Circulating microRNAs as biomarkers in progressive multiple sclerosis

Vistbakka, Julia; Elovaara, Irina; Lehtimäki, Terho; Hagman, Sanna

doi:10.1177/1352458516651141

Cited by 74 publications

(47 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our previous study, we have found it to be predominantly expressed in PPMS in comparison both with SPMS and HC. 12 The existing discrepancy between the results can be partly explained by the relatively small size of PPMS cohort.…”

Section: Ta B L E 3 Circulating Mirnas Expression Levels In Female Anmentioning

confidence: 99%

“…Notably, our previous study on circulating miRNAs in progressive subtypes of MS showed similar picture revealing upregulation of miR-191 both in PPMS and in SPMS without differences between them. 12 where their levels were downregulated in CSF but upregulated in blood in comparison with neurologically healthy subjects. 16 The exact function of miR-191 in immune systems is not clarified yet, but it has been shown to support cytokine-dependent naïve, memory, and regulatory T-cell survival and thereby to maintain immune homeostasis by controlling the levels of insulin receptor substrate 1 (IRS1).…”

Section: Ta B L E 3 Circulating Mirnas Expression Levels In Female Anmentioning

confidence: 99%

“…[9][10][11] For example, miR-660, miR-939, and miR-145 were found to be aberrantly expressed in plasma of RRMS patients, 11 while let-7c, let-7d, miR-92a-1*, miR-135a, miR-145, miR-454, miR-500, and miR-574-3p were differentially expressed in plasma of patients with secondary progressive MS (SPMS) in comparison with RRMS. 10 This study is based on our previous study on circulating miR-NAs in progressive subtypes of MS, 12 where overexpression of miR-128-3p, miR-24-3p, miR-191-5p, and miR-376c-3p was detected. 10 This study is based on our previous study on circulating miR-NAs in progressive subtypes of MS, 12 where overexpression of miR-128-3p, miR-24-3p, miR-191-5p, and miR-376c-3p was detected.…”

Section: Evaluation Of Serum Mir-191-5p Mir-24-3p Mir-128-3p and Mmentioning

confidence: 99%

“…9 In addition, miR-15b, miR-23a, and miR-223 were downregulated in serum of both RRMS and primary progressive MS (PPMS) patients, with no prominent differences between the MS subtypes. 10 This study is based on our previous study on circulating miR-NAs in progressive subtypes of MS, 12 where overexpression of miR-128-3p, miR-24-3p, miR-191-5p, and miR-376c-3p was detected.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Ta B L E 3 Circulating Mirnas Expression Levels In Female Anmentioning

confidence: 99%

Section: Ta B L E 3 Circulating Mirnas Expression Levels In Female Anmentioning

confidence: 99%

Section: Evaluation Of Serum Mir-191-5p Mir-24-3p Mir-128-3p and Mmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In detail, the upregulation of miR-191-5p was found in both progressive MS subtypes, while miR-376c-3p was over expressed only in PPMS. In order to validate their specificity for progressive forms of MS, additional studies on a large PMS cohort are needed [52]. …”

Section: Biological Markers In Progressive Multiple Sclerosis (Pms)mentioning

confidence: 99%

A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives

D’Amico

Patti

Zanghì

et al. 2016

IJMS

View full text Add to dashboard Cite

Using the term of progressive multiple sclerosis (PMS), we considered a combined population of persons with secondary progressive MS (SPMS) and primary progressive MS (PPMS). These forms of MS cannot be challenged with efficacy by the licensed therapy. In the last years, several measures of risk estimation were developed for predicting clinical course in MS, but none is specific for the PMS forms. Personalized medicine is a therapeutic approach, based on identifying what might be the best therapy for an individual patient, taking into account the risk profile. We need to achieve more accurate estimates of useful predictors in PMS, including unconventional and qualitative markers which are not yet currently available or practicable routine diagnostics. The evaluation of an individual patient is based on the profile of disease activity.Within the neurology field, PMS is one of the fastest-moving going into the future.

show abstract

Erythrocyte microRNAs show biomarker potential and implicate multiple sclerosis susceptibility genes

Groen

Maltby

Scott

et al. 2020

Clinical & Translational Med

View full text Add to dashboard Cite

Background Multiple sclerosis is a demyelinating autoimmune disease, for which there is no blood‐borne biomarker. Erythrocytes may provide a source of such biomarkers as they contain microRNAs. MicroRNAs regulate protein translation through complementary binding to messenger RNA. As erythrocytes are transcriptionally inactive, their microRNA profiles may be less susceptible to variation. The aim of this study was to assess the biomarker potential of erythrocyte microRNAs for multiple sclerosis and assess the potential contribution of erythrocyte‐derived extracellular vesicle microRNAs to pathology. Methods Erythrocytes were isolated from whole blood by density gradient centrifugation. Erythrocyte microRNAs of a discovery cohort (23 multiple sclerosis patients and 22 healthy controls) were sequenced. Increased expression of miR‐183 cluster microRNAs (hsa‐miR‐96‐5p, hsa‐miR‐182‐5p and hsa‐miR‐183‐5p) was validated in an independent cohort of 42 patients and 45 healthy and pathological (migraine) controls. Erythrocyte‐derived extracellular vesicles were created ex vivo and their microRNAs were sequenced. Targets of microRNAs were predicted using miRDIP. Results Hsa‐miR‐182‐5p and hsa‐miR‐183‐5p were able to discriminate relapsing multiple sclerosis patients from migraine patients and/or healthy controls with 89‐94% accuracy and around 90% specificity. Hsa‐miR‐182‐5p and hsa‐miR‐183‐5p expression correlated with measures of physical disability and hsa‐miR‐96‐5p expression correlated with measures of cognitive disability in multiple sclerosis. Erythrocytes were found to selectively package microRNAs into extracellular vesicles and 34 microRNAs were found to be differentially packaged between healthy controls and multiple sclerosis patients. Several gene targets of differentially expressed and packaged erythrocyte microRNAs overlapped with multiple sclerosis susceptibility genes. Gene enrichment analysis indicated involvement in nervous system development and histone H3‐K27 demethylation. Conclusions Erythrocyte miR‐183 cluster members may be developed into specific multiple sclerosis biomarkers that could assist with diagnosis and disability monitoring. Erythrocyte and their extracellular microRNAs were shown to target multiple sclerosis susceptibility genes and may be contributing to the pathophysiology via previously identified routes.

show abstract

Circulating microRNAs as biomarkers in progressive multiple sclerosis

Abstract: We detected overexpression of four miRNAs that have not been previously associated with progressive forms of MS. The increased expression of circulating miR-191-5p seems to be associated with progressive forms of MS, while miR-128-3p seems to be associated mostly with PPMS.

Cited by 74 publications

References 37 publications

Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients

Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients

A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives

Erythrocyte microRNAs show biomarker potential and implicate multiple sclerosis susceptibility genes

Contact Info

Product

Resources

About